{
    "clinical_study": {
        "@rank": "70730", 
        "brief_summary": {
            "textblock": "OBJECTIVES: I.   Assess the safety and effectiveness of budesonide in patients with primary\n      sclerosing cholangitis or primary biliary cirrhosis experiencing a suboptimal response to\n      ursodeoxycholic acid.\n\n      II.  Estimate the efficacy of this therapy in these patient groups as a means of evaluating\n      the feasibility of a long-term randomized trial."
        }, 
        "brief_title": "Pilot Study of Budesonide for Patients With Primary Sclerosing Cholangitis", 
        "condition": [
            "Cholangitis, Sclerosing", 
            "Liver Cirrhosis, Biliary"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Cholangitis", 
                "Cholangitis, Sclerosing", 
                "Liver Cirrhosis", 
                "Fibrosis", 
                "Liver Cirrhosis, Biliary"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE:\n\n      Patients receive budesonide by mouth 3 times daily for a minimum of 6 months. If liver\n      biochemistries become normal, dosage is reduced to once daily. Treatment discontinues after\n      1 year."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics--\n\n        Pathologically confirmed primary sclerosing cholangitis (PSC) meeting the following\n        criteria:\n\n          -  Chronic cholestatic disease for at least 6 months\n\n          -  Liver biopsy within the past 6 months compatible with the diagnosis of PSC Intra\n             and/or extrahepatic biliary duct obstruction, beading, or narrowing\n\n        OR\n\n        Pathologically confirmed primary biliary cirrhosis (PBC) that is experiencing suboptimal\n        response to ursodeoxycholic acid and meeting the following criteria:\n\n          -  Chronic cholestatic liver disease for at least 6 months\n\n          -  Positive antimitochondrial antibody\n\n          -  No biliary obstruction by ultrasound, CT, or cholangiography\n\n          -  Prior liver biopsy compatible with diagnosis of PBC\n\n          -  Received ursodeoxycholic acid for at least 6 months\n\n        --Prior/Concurrent Therapy--\n\n        Biologic therapy:\n\n          -  At least 3 months since prior D-penicillamine\n\n          -  No planned transplantation for at least 1 year\n\n        Chemotherapy:\n\n          -  At least 3 months (6 months for PBC) since prior cyclosporin, colchicine,\n             azathioprine, or methotrexate\n\n          -  At least 6 months since prior chlorambucil (PBC only)\n\n        Endocrine therapy: At least 3 months (6 months for PBC) since prior corticosteroids\n\n        Surgery: No prior intraductal stones or operations on the biliary tree except\n        cholecystectomy (PSC only)\n\n        Other:\n\n          -  At least 3 months since prior pentoxifylline, ursodeoxycholic acid, or nicotine (PSC\n             only)\n\n          -  At least 6 months since prior chenodeoxycholic acid (PBC only)\n\n        --Patient Characteristics--\n\n        Life expectancy: At least 3 years\n\n        Hematopoietic: Not specified\n\n        Hepatic:\n\n          -  Alkaline phosphatase at least 2 times upper limits of normal\n\n          -  No chronic hepatitis B infection\n\n          -  No hepatitis C infection\n\n          -  No autoimmune hepatitis\n\n          -  Bilirubin no greater than 4 mg/dL (PBC only)\n\n        Cardiovascular: No severe cardiopulmonary disease\n\n        Other:\n\n          -  No concurrent advanced malignancy\n\n          -  At least 3 months since prior inflammatory bowel disease requiring specific treatment\n             except maintenance therapy (PSC only)\n\n          -  No anticipated need for transplantation within 1 year\n\n          -  Not pregnant\n\n          -  No liver disease of other etiology such as:\n\n        Chronic alcoholic liver disease\n\n        Hemochromatosis\n\n        Wilson's disease\n\n        Congenital biliary disease\n\n        Cholangiocarcinoma\n\n        No recurrent ascending cholangitis requiring hospitalization more than 2 times per year\n        (PSC only)\n\n        At least 1 year since prior active peptic ulcer\n\n        No recurrent variceal bleeds\n\n        No spontaneous encephalopathy\n\n        No diuretic-resistant ascites"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "50", 
        "firstreceived_date": "February 24, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004842", 
            "org_study_id": "199/13922", 
            "secondary_id": [
                "MAYOC-41296", 
                "MAYOC-DK52344"
            ]
        }, 
        "intervention": {
            "intervention_name": "budesonide", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Budesonide"
        }, 
        "keyword": [
            "cirrhosis", 
            "gastrointestinal disorders", 
            "primary biliary cirrhosis", 
            "primary sclerosing cholangitis", 
            "rare disease"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Keith D. Lindor", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004842"
        }, 
        "source": "Office of Rare Diseases (ORD)", 
        "sponsors": {
            "collaborator": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "October 1998", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 1998"
    }, 
    "geocoordinates": {}
}